Top Page
AdAlta Ltd.
(Sydney:1AD)
AdAlta Ltd. (1AD) vs. iShares MSCI Australia ETF (EWA)
AdAlta Ltd. Business Overview & Revenue Model
AdAlta Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 677.01K | 677.01K | 1.74M | 3.47M | 2.75M | 848.19K |
| Gross Profit | 457.50K | 457.50K | 1.51M | 3.44M | 2.49M | 848.19K |
| EBITDA | -4.45M | -4.45M | -6.94M | -7.58M | -7.31M | -8.36M |
| Net Income | -4.50M | -4.50M | -5.38M | -4.85M | -6.06M | -5.63M |
Balance Sheet | ||||||
| Total Assets | 2.14M | 2.14M | 5.57M | 7.73M | 10.65M | 9.05M |
| Cash, Cash Equivalents and Short-Term Investments | 1.31M | 1.31M | 3.13M | 4.79M | 8.66M | 5.79M |
| Total Debt | 1.77M | 1.77M | 2.70M | 4.01M | 4.00M | 1.69M |
| Total Liabilities | 2.74M | 2.74M | 3.54M | 5.82M | 5.27M | 2.66M |
| Stockholders Equity | -598.24K | -598.24K | 2.03M | 1.91M | 5.38M | 6.39M |
Cash Flow | ||||||
| Free Cash Flow | -2.94M | -2.94M | -5.32M | -5.13M | -4.11M | -4.78M |
| Operating Cash Flow | -2.94M | -2.94M | -5.26M | -5.13M | -4.09M | -4.78M |
| Investing Cash Flow | 109.61K | 109.61K | -62.40K | -2.13K | -25.23K | -2.12K |
| Financing Cash Flow | 999.06K | 999.06K | 3.67M | 1.27M | 7.02M | 7.19M |
AdAlta Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$10.13M | ― | -289.05% | ― | ― | 24.09% | |
42 Neutral | AU$8.54M | -2.30 | ― | ― | ― | ― | |
40 Underperform | AU$2.17M | -4.33 | -28.49% | ― | ― | 46.43% | |
37 Underperform | AU$5.68M | ― | -628.72% | ― | ― | 31.87% | |
27 Underperform | AU$3.21M | ― | -205.70% | ― | ― | 1.03% |
AdAlta Ltd. Corporate Events
AdAlta Ltd. announced a proposed issue of securities, comprising 183,333,333 options expiring on June 3, 2028, and 366,666,667 fully paid ordinary shares, with a proposed issue date of November 26, 2025. This move is likely to impact the company’s financial positioning by potentially increasing its capital base, which could enhance its ability to fund ongoing and future projects, thereby strengthening its position in the biotechnology sector.
AdAlta Limited has successfully completed the issuance of 153,657,204 fully paid ordinary shares to sophisticated investors through a private placement. This move, announced earlier in October 2025, is part of the company’s strategic efforts to bolster its financial position and support its ongoing research and development initiatives. The issuance was conducted without disclosure to investors under specific provisions of the Corporations Act, and the company has confirmed compliance with relevant legal requirements. This development is expected to enhance AdAlta’s operational capabilities and strengthen its market position in the biotechnology sector.
AdAlta Ltd. announced the quotation of 153,657,204 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 20, 2025. This move is part of previously announced transactions and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the accessibility and visibility of its securities.
AdAlta Limited has announced a proposed issue of 153,657,204 ordinary fully paid securities, scheduled for issuance on October 17, 2025. This move is part of a placement or other type of issue, which could have implications for the company’s market positioning and stakeholder interests as it seeks to enhance its capital structure.
AdAlta Ltd. has announced a proposed issue of securities, involving the issuance of 83,333,334 options expiring in 2028 and 13,009,463 fully paid ordinary shares. This strategic move is aimed at raising capital to support the company’s ongoing research and development efforts, potentially enhancing its market position and providing new opportunities for stakeholders.
AdAlta Limited has secured a non-brokered private placement of up to A$0.5 million from a sophisticated Hong Kong investor, enhancing its capacity to pursue its ‘East to West’ cellular immunotherapy strategy. This investment, priced at a 20% premium, underscores confidence in AdAlta’s approach to integrating Asian innovations with Western markets, potentially accelerating the development and licensing of CAR-T cell therapies for solid cancers, and strengthening its market position.
AdAlta Limited has completed the issuance of 76,666,667 fully paid ordinary shares to NLSC, LLC as part of its funding arrangements. This move is part of the company’s strategy to manage its financial obligations and enhance its capital structure, potentially impacting its market positioning and stakeholder relationships.
AdAlta Ltd. has announced the issuance of 76,666,667 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code 1AD. This move is part of previously announced transactions and is expected to enhance the company’s financial position, potentially impacting its market presence and providing additional resources to advance its therapeutic developments.
AdAlta Limited announced that its Annual General Meeting (AGM) will be held on 19 November 2025 as a hybrid event in Melbourne and via Zoom. The meeting will include a business update from CEO Dr. Tim Oldham. The company is strategically positioned to leverage its expertise in cellular immunotherapies to address the underserved solid cancer market, with its innovative products like AD-214 for fibrotic diseases showing promising results in clinical studies. This positions AdAlta to potentially dominate a high-growth market segment.
AdAlta Ltd. has announced the application for quotation of 138,888,889 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, and it signifies a strategic effort to enhance the company’s financial standing and market presence, potentially impacting its operations and industry positioning positively.
AdAlta Limited is set to present at two significant events, showcasing its ‘East to West’ cellular immunotherapy strategy. The company will participate in a bi-lingual webinar hosted by Resource Connect Asia and the Asia Bio Partnering Forum in Singapore. These presentations aim to highlight AdAlta’s integration of Asian T cell therapy innovations with Western clinical practices, potentially enhancing shareholder value and positioning the company as a leader in the cellular immunotherapy market. The events are expected to bolster AdAlta’s industry positioning and provide strategic opportunities for global partnerships.
AdAlta Ltd. has announced the quotation of 166,666,667 fully paid ordinary securities on the Australian Securities Exchange (ASX) as part of a previously announced transaction. This move is expected to enhance the company’s financial flexibility and support its ongoing development projects, potentially strengthening its position in the biotechnology sector.
AdAlta Limited announced the availability of a presentation by CEO Dr. Tim Oldham at the TechKnow Invest Roadshow, emphasizing their ‘East to West’ strategy. This strategy involves licensing clinical stage products from China, developing them in Australia, and on-licensing them to Western markets, capitalizing on the CAR-T cell therapy revolution and China’s biotech innovation. This approach aims to create significant value for shareholders and position AdAlta as a leader in the growing cellular immunotherapy market, particularly for solid tumors.
AdAlta Limited is set to present at the TechKnow Invest Conference, highlighting its ‘East to West’ cellular immunotherapy strategy. The company’s CEO will discuss the impact of the China innovation boom and the potential of reprogrammed human immune cells in cancer treatment. This presentation underscores AdAlta’s strategic positioning in the rapidly growing cellular immunotherapy market, aiming to leverage Asian innovations and Western market opportunities to address the unmet needs in solid cancer treatments.
AdAlta Limited has issued 41,666,667 fully paid ordinary shares to NLSC, LLC as part of its funding arrangements, with each share priced at $0.0018. This move is part of the company’s strategic financial management, ensuring compliance with relevant corporate regulations, and it highlights AdAlta’s ongoing efforts to secure necessary funding for its operations.
AdAlta Limited has released an investor presentation highlighting its ongoing efforts to commercialize cellular immunotherapies. The company emphasizes the potential therapeutic impact of its research and development projects, although it acknowledges the inherent risks and uncertainties associated with drug development and regulatory approvals. The announcement underscores AdAlta’s commitment to advancing its projects despite the challenges, which could influence its market positioning and stakeholder interests.
AdAlta Ltd. has announced the cessation of 2,487,500 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may affect the company’s capital structure and could have implications for its financial strategy and stakeholder interests.